About Protein ERGIC-53
Protein ERGIC-53 (LMAN1) is a protein
from Homo sapiens identified by UniProt accession
P49257, 510 residues long.
MolForge cross-references it against 0 known binders and
78 disease associations.
Target properties
| Protein name | Protein ERGIC-53 |
| UniProt accession | P49257 |
| Gene | LMAN1 |
| Organism | Homo sapiens |
| Length | 510 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (78)
Diseases linked to this target (Open Targets).
- factor V and factor VIII, combined deficiency of, type 1 · score 0.72
- combined deficiency of factor V and factor VIII · score 0.37
- cardiac troponin I measurement · score 0.36
- neurodegenerative disease · score 0.32
- IGF-1 measurement · score 0.31
- eosinophil count · score 0.20
- genetic disorder · score 0.19
- late-onset Alzheimers disease · score 0.14
- cutaneous melanoma · score 0.14
- appendicular lean mass · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P49257-F1 | alphafold | PREDICTED | 79.39 | — |
Amino-acid sequence (510 residues)
MAGSRQRGLR ARVRPLFCAL LLSLGRFVRG DGVGGDPAVA LPHRRFEYKY SFKGPHLVQS DGTVPFWAHA GNAIPSSDQI RVAPSLKSQR GSVWTKTKAA FENWEVEVTF RVTGRGRIGA DGLAIWYAEN QGLEGPVFGS ADLWNGVGIF FDSFDNDGKK NNPAIVIIGN NGQIHYDHQN DGASQALASC QRDFRNKPYP VRAKITYYQN TLTVMINNGF TPDKNDYEFC AKVENMIIPA QGHFGISAAT GGLADDHDVL SFLTFQLTEP GKEPPTPDKE ISEKEKEKYQ EEFEHFQQEL DKKKEEFQKG HPDLQGQPAE EIFESVGDRE LRQVFEGQNR IHLEIKQLNR QLDMILDEQR RYVSSLTEEI SKRGAGMPGQ HGQITQQELD TVVKTQHEIL RQVNEMKNSM SETVRLVSGM QHPGSAGGVY ETTQHFIDIK EHLHIVKRDI DNLVQRNMPS NEKPKCPELP PFPSCLSTVH FIIFVVVQTV LFIGYIMYRS QQEAAAKKFF
Explore Protein ERGIC-53 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets